Borderline Findings in O-(2-[18F]-Fluoroethyl)-l-Tyrosine PET of Patients with Suspected Glioma Relapse: Role in Clinical Practice

¹Institute of Neuroscience and Medicine (INM-3/INM-4/INM-5/INM-11), Forschungszentrum Jülich, Jülich, Germany;
²Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany;
³Center of Integrated Oncology, Aachen Bonn Cologne Duesseldorf, Germany;
⁴Department of Stereotaxy and Functional Neurosurgery, Center for Neurosurgery, Faculty of Medicine and University Hospital Cologne, Cologne, Germany;
⁵Department of Neurosurgery, University of Duesseldorf, Duesseldorf, Germany;
⁶Department of Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany;
⁷University Cancer Center Frankfurt, Goethe University Hospital, Frankfurt am Main, Germany;
⁸Dr. Senckenberg Institute of Neurooncology, Goethe University Frankfurt, Frankfurt am Main, Germany;
⁹Institute of Neuroradiology, Goethe University Hospital, Frankfurt am Main, Germany;
¹⁰Department of Neurosurgery, Helios Clinics Krefeld, Krefeld, Germany;
¹¹Department of Neurosurgery, University Hospital RWTH Aachen, Aachen, Germany;
¹²JARA-BRAIN-Translational Medicine, Aachen, Germany;
¹³Department of Neurology, RWTH Aachen University, Aachen, Germany; and
¹⁴Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands